Condition 101 About Angioimmunoblastic T-cell Lymphoma

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Top Global Doctors For Angioimmunoblastic T-cell Lymphoma

View All Doctors

Latest Advances On Angioimmunoblastic T-cell Lymphoma

  • Condition: Peripheral T-cell Lymphoma
  • Journal: International journal of hematology
  • Treatment Used: Stem Cell Transplantation
  • Number of Patients: 374
  • Published —
The study researched the outcomes of stem cell transplantation for patients with peripheral T-cell lymphoma.
View All Latest Advances

Clinical Trials For Angioimmunoblastic T-cell Lymphoma

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 46
  • Start Date: July 2020
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Drug
  • Participants: 26
  • Start Date: March 31, 2020
A Single-arm, Multiple Centers, Phase II Study Evaluating Rituximab in Combination With Chidamide and Lenalidomide for Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL)
View All Clinical Trials